drugset
drugset / Trial / NCT04039230

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

NCT04039230 ↗

Phase 1/2 Active not recruiting 75 enrolled Massachusetts General Hospital Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.

Timeline

Start
2019-10-09
Primary completion
2027-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacituzumab Govitecan Monoclonal antibody — —
Subject Talazoparib Small molecule — —

Indications

breast cancer